Abstracts Archive - Page 540 of 2607 - ACR Meeting Abstracts

Abstract Number: 2482 • ACR Convergence 2023
Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis
Takayuki Fujii¹, Dana Orange², Caryn Hale², Koichi Murata¹, Hideo Onizawa¹, Akira Onishi¹, Masao Tanaka³, Akio Morinobu⁴ and Shuichi Matsuda⁵, ¹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rockefeller University, New York, NY, ³Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: This study aimed to determine predictors of treatment response and radiographic progression following the initiation of biological disease-modifying antirheumatic medications (bDMARDs) in patients with…
Abstract Number: PP03 • ACR Convergence 2023
Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Amanda Greene, Los Angeles, CA
Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE). I was immediately prescribed high dose corticosteroids. My body and…
Abstract Number: 2263 • ACR Convergence 2023
Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Eric Morand¹, Richard Furie², Christine Peschken³, Martin Aringer⁴, Laurent Arnaud⁵, Barnabas Desta⁶, Tina Grünfeld Eén⁷, Alessandro Sorrentino⁸, Stephanie Chen⁹ and Bo Ding⁷, ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Northwell Health, Manhasset, NY, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Carl Gustav Carus, Dresden, Germany, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁸Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international, multicenter SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with SLE in relation to their type 1 interferon gene signature…
Abstract Number: 2261 • ACR Convergence 2023
Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
Rangi Kandane-Rathnayake¹, Dominique Milea², Worawit Louthrenoo³, Alberta Hoi⁴, Vera Golder¹, Jiacai Cho⁵, Aisha Lateef⁵, Shue-Fen Luo⁶, Yeong-Jian J Wu⁷, Laniyati Hamijoyo⁸, Sargunan Sockalingam⁹, Zhanguo Li¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Masayoshi Harigai¹², Yasuhiro Katsumata¹², Madelynn Chan¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁵, Sean O’Neill¹⁶, Fiona Goldblatt¹⁷, Shereen Oon¹⁸, Xiaomeng Xu², Aldo Amador Navarro Rojas¹⁹, Sang-Cheol Bae²⁰, Chak Sing Lau²¹, Mandana Nikpour²² and Eric Morand²³, ¹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ²GlaxoSmithKline, Value Evidence and Outcomes, Singapore, Singapore, ³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ⁵National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁶Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹⁰Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹¹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁴St Vincent’s Hospital Melbourne, Department of Rheumatology, Melbourne, Australia, ¹⁵Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁶Department of Medicine, University of New South Wales, Kensington, Australia, ¹⁷Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ¹⁸University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ¹⁹GlaxoSmithKline, Medical Affairs, Singapore, Singapore, ²⁰Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²¹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ²³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: Up to 50% of patients with SLE develop irreversible organ damage within 10 years of diagnosis, and most experience recurrent disease flares of varying…
Abstract Number: PP13 • ACR Convergence 2023
My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Lisa Rubenstein, Sjögren's Foundation, Los Angeles, CA

Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
Abstract Number: 2272 • ACR Convergence 2023
Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States
Rashmi Dhital¹, Ioannis Karageorgiou², Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²William Beaumont University Hospital, Troy, MI, ³William Beaumont University Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently visit the emergency department (ED) due to the complex disease course. Previous research highlights infection and pain…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Yuichiro fujieda¹, Kodai Sakiyama¹, Nobuya Abe¹, Ryo Hisada¹, Michihito Kono¹, Masaru Kato¹, Olga Amengual², Khin Khin Tha³, Hisashi Shirakawa⁴ and Tatsuya Atsuma⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto, Japan, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 2271 • ACR Convergence 2023
Longitudinal Changes in Type 1 & Type 2 SLE Activity
Amanda Eudy¹, Jennifer Rogers², Daniel Wojdyla³, Kai Sun², Rebecca Sadun², Mithu Maheswaranathan⁴, Jayanth Doss², Lisa Criscione-Schreiber⁴ and Megan Clowse⁵, ¹Duke University, Raleigh, NC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, rash, serositis and nephritis (Type 1 SLE), and symptoms…
Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Dori Abel¹, Joyce Chang², Jon Burnham³, Chen Kenyon⁴ and Sabrina Gmuca⁵, ¹Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Boston Children's Hospital, Boston, MA, ³Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Je Hee Shin¹, Jung Yoon Pyo², Minkyung Han³, Myeongjee Lee³, Sung Min Lim¹, Jee Yeon Baek¹, Ji Young Lee¹, Ji-Man Kang¹, InKyung Jung³ and Jong Gyun Ahn¹, ¹Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ³Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: 134 • 2023 Pediatric Rheumatology Symposium
Patient-Provider Communication in Pediatric Rheumatology
Julie Samuels, Emma Wojtal and Rebecca Trachtman, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Communication is an essential part of medical care, especially in Pediatric Rheumatology where children have varying complex chronic diseases. However, there is paucity of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].